Pharma Pipeline Intelligence MCP Server

Drug pipeline competitive intelligence for pharmaceutical companies, biotech investors, and medical affairs teams starts here. This MCP server orchestrates 7 live data sources — ClinicalTrials.gov, FDA, EMA, USPTO, and PubMed — to produce a composite Pipeline Threat Score (0-100) with four specialized sub-models. Connect once to any MCP-compatible AI assistant and ask structured pipeline questions in plain language.

The server runs as a persistent Apify Standby actor exposed over HTTP using the MCP protocol. When you call a tool, it fans out to up to 7 actors in parallel, applies four scoring models to the combined data, and returns structured JSON with scores, signals, and supporting records. No code, no API keys to manage for the underlying databases, and no subscriptions.

⬇️ What data can you access?

Why use Pharma Pipeline Intelligence MCP?

Building a competitive pipeline analysis by hand means querying ClinicalTrials.gov, navigating the openFDA API, searching USPTO full-text, pulling EMA product data, and combing PubMed — across different schemas, rate limits, and data models. A thorough analyst might spend two days assembling the picture for a single drug. It still arrives without scoring, signal detection, or a cross-source threat rating.

This MCP server automates the entire process. One tool call to generate_pipeline_threat_report fires 7 actors simultaneously, applies four purpose-built scoring models, and returns a composite risk report in under two minutes.

Platform benefits included with every run:

• Scheduling — run weekly competitive landscape sweeps via Apify Scheduler with no cron infrastructure
• API access — trigger any tool from Python, JavaScript, or any HTTP client using the MCP protocol
• Standby mode — the server stays warm with no cold-start latency; requests are handled in milliseconds
• Spending limits — set per-session budget caps so AI assistants cannot overspend on exploratory queries
• Integrations — connect to Zapier, Make, webhooks, or downstream CRM workflows after each tool call

Features

• 8 specialized MCP tools covering every dimension of drug pipeline intelligence, from clinical trials to patent exclusivity to literature velocity
• 7-actor parallel orchestration — the generate_pipeline_threat_report tool fans out to all 7 data sources simultaneously, cutting total latency versus sequential calls
• Pipeline Threat Score with 4 sub-models — Phase 3 density contributes 8 points per competitor (max 40), trial volume caps at 20, recent FDA approvals at 15, EMA approvals at 10, with recall activity reducing threat by up to 15 points
• First-Mover Advantage Index — patent portfolio scores up to 30 points (5 patents = 30), exclusivity duration adds 2.5 points per year of remaining protection (max 25), trial phase lead scores up to 25 points
• Adverse Event Divergence detection — death reports score 7 points each (max 35), serious event ratio above 30% triggers an elevated signal, hospitalization burden adds up to 20 points with log-normalized volume scoring
• Literature Momentum acceleration detection — compares publication counts from the last 2 years against the prior 2-year period; 20% or greater growth triggers an acceleration signal
• Phase detection across naming conventions — recognizes both Arabic numeral (Phase 1, 2, 3, 4) and Roman numeral (Phase I, II, III, IV) trial phase labels from ClinicalTrials.gov
• Composite scoring formula — Pipeline Threat 30% + Adverse Events 25% + Literature Momentum 25% + First-Mover Inverted 20%, calibrated so a strong first-mover position reduces overall risk
• 4-tier risk classification — LOW (0-25), MODERATE (26-50), HIGH (51-75), CRITICAL (76-100) with plain-English signal explanations for each boundary crossed
• Recall intelligence as negative pressure — competitor drug recalls reduce the Pipeline Threat Score (more failed competitors = less threat), a nuance absent from most competitive tools
• Top 10 adverse reaction extraction — MedDRA reaction terms aggregated by frequency across all FAERS reports, sorted descending
• FDA vs EMA regulatory gap analysis — compare_regulatory_pathways computes the raw approval count difference between FDA and EMA, flagging divergence in regulatory acceptance across markets
• Spending limit enforcement — every tool checks Actor.charge() before executing and returns a structured error if the session budget is exhausted

Use cases for drug pipeline competitive intelligence

Biotech investment thesis validation

Pre-IPO analysts and venture partners tracking clinical-stage companies need to quantify pipeline risk before committing capital. The generate_pipeline_threat_report tool produces a scored assessment of competitive crowding, adverse event signals for the target compound, patent protection duration, and research momentum — all in a single call. Compare scores across candidate investments to rank risk-adjusted opportunity.

Competitive landscape monitoring for business development

BD teams evaluating in-licensing targets or co-development partnerships need to understand how crowded a therapeutic area is before negotiating deal terms. The analyze_competitive_landscape tool returns FDA approvals, EMA authorizations, active trial counts, and a Pipeline Threat Score for any drug class or indication, giving deal teams a data-backed view of competitive density within minutes.

Patent cliff and generic entry strategy

Generic drug manufacturers and biosimilar developers tracking branded drug exclusivity windows need precise patent expiry data. The track_patent_exclusivity tool pulls USPTO filings, extracts expiration dates, calculates remaining years of exclusivity, and returns a First-Mover Advantage score — identifying which drugs are approaching patent cliffs and when generic entry windows open.

Safety signal surveillance for medical affairs

Pharmacovigilance and medical affairs teams monitoring the safety profile of a drug or its competitors need early detection of adverse event pattern shifts. The detect_adverse_event_signals tool analyzes FAERS reports, classifies outcomes as NORMAL / ELEVATED / CONCERNING / CRITICAL, and surfaces the top 10 MedDRA reaction terms — complementing enterprise pharmacovigilance systems with a rapid public-data view.

Research strategy and emerging area identification

R&D strategy teams need to identify therapeutic areas gaining momentum before competitors commit resources. The assess_literature_momentum tool scores publication velocity from PubMed, detects acceleration (20% growth threshold), and identifies the top journals covering a research space — signaling where the field is heading before clinical programs are announced.

Regulatory pathway planning for market access

Global market access teams planning multi-region launches need to understand where regulatory gaps exist between FDA and EMA. The compare_regulatory_pathways tool queries both agencies in parallel and returns approval counts with a regulatory gap metric, helping teams sequence launches and anticipate where additional submissions will be needed.

How to use drug pipeline intelligence tools

1. Connect the MCP server to your AI assistant — Add the server URL to your Claude Desktop, Cursor, or Windsurf config (see connection instructions below). No API key setup is needed for the underlying databases.
2. Ask your AI a natural-language question — For example: "Analyze the competitive landscape for GLP-1 agonists in obesity" or "Generate a pipeline threat report for Vertex Pharmaceuticals and ivacaftor."
3. Review the scored output — The AI presents Pipeline Threat Scores, sub-model breakdowns, and plain-English signals derived from live regulatory and clinical data.
4. Set a spending limit — In Apify Console, configure a maximum spend per session to control costs on exploratory research sessions. The server stops when the limit is reached.

⬇️ MCP tools

Tool input parameters

⬆️ Output example

{
  "company": "Vertex Pharmaceuticals",
  "drug": "ivacaftor",
  "compositeScore": 38,
  "riskLevel": "MODERATE",
  "pipelineThreat": {
    "score": 24,
    "competitorCount": 11,
    "phaseDistribution": {
      "Phase 2": 4,
      "Phase 3": 2,
      "Phase 1": 3
    },
    "sameIndicationTrials": 9,
    "recentApprovals": 2,
    "recentRecalls": 0,
    "threatLevel": "LOW",
    "signals": [
      "2 recent FDA approvals in class"
    ]
  },
  "firstMoverAdvantage": {
    "score": 76,
    "patentsCovering": 5,
    "earliestPatentExpiry": "2031-08-14",
    "yearsOfExclusivity": 5.4,
    "trialPhaseLead": 4,
    "approvalPathwayClear": true,
    "signals": [
      "5.4 years patent exclusivity remaining",
      "Already has 2 FDA approval(s)"
    ]
  },
  "adverseEventDivergence": {
    "score": 29,
    "totalReports": 214,
    "seriousEvents": 58,
    "deathReports": 1,
    "hospitalizationReports": 12,
    "seriousRatio": 0.271,
    "divergenceLevel": "ELEVATED",
    "topReactions": [
      { "term": "COUGH", "count": 31 },
      { "term": "NAUSEA", "count": 24 },
      { "term": "DIARRHOEA", "count": 19 },
      { "term": "RASH", "count": 14 },
      { "term": "FATIGUE", "count": 11 }
    ],
    "signals": []
  },
  "literatureMomentum": {
    "score": 52,
    "publicationCount": 47,
    "recentPublications": 18,
    "yearlyTrend": {
      "2022": 8,
      "2023": 11,
      "2024": 15,
      "2025": 13
    },
    "accelerating": true,
    "topJournals": [
      "Journal of Cystic Fibrosis",
      "American Journal of Respiratory and Critical Care Medicine",
      "Thorax",
      "Pediatric Pulmonology",
      "ERJ Open Research"
    ],
    "signals": [
      "18 publications in last 2 years",
      "Publication rate accelerating (28 recent vs 19 prior 2yr)"
    ]
  },
  "allSignals": [
    "2 recent FDA approvals in class",
    "5.4 years patent exclusivity remaining",
    "Already has 2 FDA approval(s)",
    "18 publications in last 2 years",
    "Publication rate accelerating (28 recent vs 19 prior 2yr)"
  ]
}

⬆️ Output fields

How much does it cost to run drug pipeline analysis?

Pharma Pipeline Intelligence MCP uses pay-per-event pricing — each tool call costs $0.045. There is no subscription, no minimum commitment, and no charge for idle time between calls.

You can set a maximum spending limit per session in Apify Console. The server stops charging and returns a structured error once your budget is reached — no surprise overruns when an AI assistant runs exploratory queries.

Comparable dedicated pharma intelligence platforms (Citeline Pharma R&D, Clarivate Cortellis, GlobalData) charge $15,000–$50,000 per year for similar regulatory and pipeline data access. Most users of this MCP spend $2–$10 per month with no subscription commitment.

How to connect this MCP server

Claude Desktop

Add to your claude_desktop_config.json:

{
  "mcpServers": {
    "pharma-pipeline": {
      "url": "https://pharma-pipeline-intelligence-mcp.apify.actor/mcp",
      "headers": {
        "Authorization": "Bearer YOUR_APIFY_TOKEN"
      }
    }
  }
}

Cursor

In Cursor Settings → MCP → Add Server:

{
  "pharma-pipeline": {
    "url": "https://pharma-pipeline-intelligence-mcp.apify.actor/mcp",
    "headers": {
      "Authorization": "Bearer YOUR_APIFY_TOKEN"
    }
  }
}

Programmatic HTTP (cURL)

# Call analyze_competitive_landscape
curl -X POST "https://pharma-pipeline-intelligence-mcp.apify.actor/mcp" \
  -H "Content-Type: application/json" \
  -H "Authorization: Bearer YOUR_APIFY_TOKEN" \
  -d '{"jsonrpc":"2.0","method":"tools/call","params":{"name":"analyze_competitive_landscape","arguments":{"query":"GLP-1 agonist obesity"}},"id":1}'

# Call generate_pipeline_threat_report
curl -X POST "https://pharma-pipeline-intelligence-mcp.apify.actor/mcp" \
  -H "Content-Type: application/json" \
  -H "Authorization: Bearer YOUR_APIFY_TOKEN" \
  -d '{"jsonrpc":"2.0","method":"tools/call","params":{"name":"generate_pipeline_threat_report","arguments":{"company":"Novo Nordisk","drug":"semaglutide","indication":"obesity"}},"id":2}'

Python

import httpx
import json

url = "https://pharma-pipeline-intelligence-mcp.apify.actor/mcp"
headers = {
    "Content-Type": "application/json",
    "Authorization": "Bearer YOUR_APIFY_TOKEN",
}

payload = {
    "jsonrpc": "2.0",
    "method": "tools/call",
    "params": {
        "name": "generate_pipeline_threat_report",
        "arguments": {
            "company": "Novo Nordisk",
            "drug": "semaglutide",
            "indication": "obesity"
        }
    },
    "id": 1
}

response = httpx.post(url, headers=headers, json=payload)
result = response.json()
report = json.loads(result["result"]["content"][0]["text"])

print(f"Drug: {report['drug']}")
print(f"Composite Score: {report['compositeScore']}/100 — {report['riskLevel']}")
print(f"Pipeline Threat: {report['pipelineThreat']['score']} ({report['pipelineThreat']['threatLevel']})")
print(f"First-Mover Advantage: {report['firstMoverAdvantage']['score']}")
print(f"Patent Exclusivity: {report['firstMoverAdvantage']['yearsOfExclusivity']} years remaining")
print(f"Literature Accelerating: {report['literatureMomentum']['accelerating']}")
print("Signals:")
for signal in report["allSignals"]:
    print(f"  - {signal}")

JavaScript

const response = await fetch("https://pharma-pipeline-intelligence-mcp.apify.actor/mcp", {
  method: "POST",
  headers: {
    "Content-Type": "application/json",
    "Authorization": "Bearer YOUR_APIFY_TOKEN",
  },
  body: JSON.stringify({
    jsonrpc: "2.0",
    method: "tools/call",
    params: {
      name: "generate_pipeline_threat_report",
      arguments: {
        company: "Novo Nordisk",
        drug: "semaglutide",
        indication: "obesity",
      },
    },
    id: 1,
  }),
});

const result = await response.json();
const report = JSON.parse(result.result.content[0].text);

console.log(`${report.drug} — Score: ${report.compositeScore}/100 (${report.riskLevel})`);
console.log(`First-Mover: ${report.firstMoverAdvantage.score}, Exclusivity: ${report.firstMoverAdvantage.yearsOfExclusivity}yr`);
console.log(`Adverse Event Divergence: ${report.adverseEventDivergence.divergenceLevel}`);
report.allSignals.forEach(s => console.log(`  Signal: ${s}`));

This MCP also works with Windsurf, Cline, Zed, and any other client that supports the MCP protocol over HTTP.

How Pharma Pipeline Intelligence MCP works

Data collection: parallel actor orchestration

When you call generate_pipeline_threat_report, the server dispatches 7 Apify actors simultaneously using Promise.allSettled. Each actor queries its respective government database — ClinicalTrials.gov, openFDA FAERS, FDA approvals, FDA enforcement, PubMed, USPTO full-text search, and EMA product database — with 256 MB memory allocation and a 120-second timeout per actor. If any single actor fails, the others complete normally and the scoring models receive empty arrays for the failed source, preventing a single API outage from breaking the entire report.

Scoring model 1: Pipeline Threat Score

The Pipeline Threat model evaluates competitive pressure in a therapeutic area. Phase 3 trial competitors carry the highest weight — each Phase 3 trial adds 8 points, capped at 40 (5 Phase 3 competitors = maximum score for this component). The model detects phase labels in both Arabic numeral format (Phase 3) and Roman numeral format (Phase III) to handle ClinicalTrials.gov naming inconsistencies. Trial volume adds up to 20 points (2 points per trial). Recent FDA approvals in the same class add up to 15 points (5 per approval). EMA authorizations add up to 10 points (3 per authorization). Competitor drug recalls act as negative pressure, reducing the score by up to 15 points (5 per recall) — a market where competitors are failing in recalls represents lower threat. Raw score is clamped to 0-100.

Scoring model 2: First-Mover Advantage Index

The First-Mover model assesses the subject drug's defensive position. Patent portfolio breadth contributes up to 30 points (6 points per patent). Exclusivity duration adds 2.5 points per year of remaining protection (max 25 points), calculated from patent expiration dates found in USPTO data using the earliest expiry across all patents. The model raises a patent cliff warning if fewer than 2 years of exclusivity remain. Trial phase lead (the highest clinical phase among found trials) contributes up to 25 points (6.25 per phase level). Existing FDA approvals add 10 points each up to 20, representing the maximum first-mover position. The First-Mover score is then inverted in the composite formula (100 - score), so a strong first-mover position reduces overall risk.

Scoring model 3: Adverse Event Divergence

The Adverse Event model analyzes FDA FAERS reports for a drug. Death reports carry the highest weight: 7 points each, capped at 35 — 5 or more deaths triggers the maximum component score. Serious event ratio uses the fraction of total reports classified as serious, scoring up to 25 points (ratio × 50); a ratio above 30% triggers a signal, as this exceeds typical drug class averages. Hospitalization burden adds up to 20 points (4 per hospitalization report). Log-normalized volume scoring adds up to 20 points using log₂(totalReports) × 3, capturing the signal in report volume without over-weighting prolific reporters. MedDRA reaction terms are extracted from nested patient.reaction[].reactionmeddrapt fields and aggregated by frequency. Divergence levels: NORMAL (0-24), ELEVATED (25-49), CONCERNING (50-74), CRITICAL (75-100).

Scoring model 4: Literature Momentum

The Literature Momentum model measures publication acceleration using PubMed data. Publication counts by year are extracted from publicationDate, pubDate, and date fields. The acceleration test compares the sum of current year and prior year counts against the two years before that — acceleration is flagged when the recent 2-year total exceeds the prior 2-year total by 20% or more. Volume score contributes up to 30 points (3 per publication). Recency score adds up to 30 points (5 per recent publication). The acceleration ratio adds up to 25 points. Journal diversity — the number of unique journals across all publications — contributes up to 15 points (3 per unique journal), capturing the difference between a niche drug studied in one journal versus a drug generating broad cross-disciplinary interest.

Composite scoring formula

The four sub-model scores combine with fixed weights: Pipeline Threat 30% + Adverse Event Divergence 25% + Literature Momentum 25% + (100 − First-Mover Advantage) 20%. The First-Mover component is inverted because a drug with strong patent protection and existing approvals faces lower overall risk. The composite is rounded to the nearest integer and classified as LOW (0-25), MODERATE (26-50), HIGH (51-75), or CRITICAL (76-100).

Tips for best results

1. Use specific drug names over brand names for adverse event queries. FAERS data is indexed by active ingredient (e.g., "semaglutide") rather than brand name (e.g., "Ozempic"). Using the INN increases FAERS match rates significantly.
2. Add indication to generate_pipeline_threat_report when you want area-specific trial data. Without an indication, the search is drug-name only. Adding indication: "type 2 diabetes" appends it to the ClinicalTrials.gov query and retrieves more relevant competitors.
3. Run detect_adverse_event_signals separately if FAERS signal depth matters. The comprehensive report limits FAERS to 100 records. Running detect_adverse_event_signals alone with a higher limit (up to 500) gives a richer adverse event picture for pharmacovigilance work.
4. Interpret the Pipeline Threat Score directionally, not absolutely. A score of 65 (HIGH) means the therapeutic area is competitive — it does not mean the drug will fail. Use it to prioritize which areas need deeper manual research.
5. Set a spending limit before running exploratory AI sessions. When using an AI assistant with this MCP, the assistant may chain multiple tool calls autonomously. Set a per-session cap in Apify Console to prevent unexpected charges from extended research sessions.
6. Combine track_patent_exclusivity with monitor_drug_recalls for generic entry targeting. A drug with low exclusivity years remaining and recent recalls on originator products represents a higher-priority generic opportunity than the Pipeline Threat Score alone would show.
7. Compare yearlyTrend data across multiple drugs to identify emerging therapeutic areas. Drugs with flat or declining publication trends indicate mature markets; accelerating trends signal areas attracting new research investment and likely future competition.

Combine with other Apify actors

Limitations

• Data currency depends on source update frequency. ClinicalTrials.gov is updated by study sponsors, who may lag by days to weeks. FAERS data reflects voluntary reporting and has known under-reporting. Patent expiry calculations are estimates based on filing dates found in USPTO records and may not capture supplementary protection certificates (SPCs) or patent term extensions.
• Phase 3 count measures competition in the area, not against a specific mechanism. If your drug targets a specific receptor subtype, the trial phase counts may include mechanistically unrelated compounds in the same broad indication.
• The Adverse Event Divergence Score is relative, not absolute. A score of 40 means the signal pattern is elevated — it does not indicate regulatory action is imminent. This tool complements but does not replace CIOMS-compliant pharmacovigilance systems or MedWatch.
• Patent portfolio scoring uses a count-based heuristic. The model counts patents returned by a text search and does not perform freedom-to-operate (FTO) analysis or claim mapping. A high First-Mover score is not a legal opinion on patent coverage.
• EMA data coverage is limited to centrally authorized products. Nationally authorized medicines in EU member states are not included in the EMA database query.
• Literature Momentum acceleration uses a simple ratio test. The 20% threshold is a rule-of-thumb, not a statistically validated threshold. For clinical research strategy decisions, supplement with manual journal review.
• The generate_pipeline_threat_report tool caps most sources at 50 results per actor. For drugs with very large FAERS or ClinicalTrials.gov footprints, the scores reflect a sample. Run individual tools with higher limits for exhaustive analysis.
• No real-time price data or market share information. This MCP covers regulatory and scientific data only. For commercial market data, pair with a business intelligence source.

Integrations

• Apify API — Call this MCP programmatically from any pipeline; wrap in retry logic for production pharmacovigilance workflows
• Webhooks — Trigger downstream CRM or Slack notifications after each pipeline threat report completes
• Zapier — Automate weekly competitive landscape sweeps and push results to Google Sheets or HubSpot
• Make — Build no-code pharmacovigilance monitoring workflows that fire daily FAERS signal checks
• Google Sheets — Export Pipeline Threat Scores over time to track competitive position drift across a therapeutic area portfolio
• LangChain / LlamaIndex — Use structured MCP output as grounded context for RAG pipelines building pharmaceutical research assistants

❓ FAQ

How current is the clinical trial data returned by this MCP? Clinical trial data is fetched live from ClinicalTrials.gov each time you call a tool. ClinicalTrials.gov is updated continuously by study sponsors, but there may be a lag of days to weeks between a protocol change and its appearance in the database. For time-critical regulatory submissions, verify data directly on ClinicalTrials.gov.

How does drug pipeline competitive scoring work and what does the composite score mean? The composite Pipeline Threat Score combines four sub-models: competitive trial density (30%), adverse event divergence (25%), literature momentum (25%), and inverted first-mover advantage (20%). A score of 70 (HIGH) means the therapeutic area is heavily contested with multiple Phase 3 competitors and accelerating research — it does not predict the drug will fail. Use it to prioritize which programs need deeper strategic analysis.

Does the adverse event analysis replace a pharmacovigilance system? No. The adverse event divergence scoring uses public FDA FAERS data, which has well-documented under-reporting biases. It provides a rapid signal detection layer from public data only. It does not replace enterprise pharmacovigilance systems, CIOMS-compliant safety databases, or regulatory-grade signal detection platforms.

How accurate is the patent exclusivity calculation? The model extracts expiration dates from USPTO patent records and calculates remaining years from the current date. It does not account for patent term extensions (PTEs), supplementary protection certificates (SPCs), or pediatric exclusivity. Treat the output as an estimate for competitive intelligence purposes — not as legal advice or FTO analysis.

Can I track a drug's competitive position over time? Yes. Call generate_pipeline_threat_report on the same drug weekly or monthly and compare composite scores over time. An increasing score trend signals a tightening competitive environment. You can automate this with Apify Scheduler and export results to Google Sheets to build a time-series view.

How is this different from Citeline Pharma R&D or Clarivate Cortellis? Commercial platforms like Citeline and Cortellis offer curated, analyst-reviewed data with proprietary enrichment and often cost $15,000–$50,000 per year. This MCP provides direct access to the same underlying public databases (FDA, EMA, ClinicalTrials.gov, USPTO, PubMed) with quantitative scoring built on top. It is faster and dramatically cheaper for teams that need to answer specific questions rather than maintain a standing research subscription.

What types of drug queries work best? Active ingredient names (INN format) return more consistent results across data sources than brand names. For example, "semaglutide" will match ClinicalTrials.gov, FAERS, and PubMed more reliably than "Ozempic." Drug class queries like "GLP-1 agonist" or "JAK inhibitor" work well for landscape analysis tools. Company name queries work for patent and literature searches.

Can I use this MCP with Claude Projects or custom GPTs? Yes. Any MCP-compatible AI client can connect to this server. For Claude Desktop or Claude Projects, add the server URL and your Apify token to the MCP config. For OpenAI GPTs or other tool-calling frameworks, call the HTTP endpoint directly from a custom action or plugin.

Is it legal to use this pharmaceutical data for competitive intelligence? All data sources queried by this MCP are public databases operated by government agencies: FDA, NIH (PubMed), USPTO, EMA, and ClinicalTrials.gov. Accessing and analyzing public government data for business research purposes is legal. For guidance on data usage in specific contexts (financial research, regulatory submissions), consult legal counsel. See Apify's guide on web scraping legality.

What happens if one of the 7 underlying actors fails during a report? The generate_pipeline_threat_report tool uses Promise.allSettled, so a failure in any single actor does not abort the run. The failed actor's data is replaced with an empty array, and the scoring models proceed with the remaining sources. The composite score will be lower than usual (fewer inputs), but you will still receive a report. Individual tool calls are single-actor and will return an error if the underlying actor fails.

How many pipeline threat reports can I run on the free Apify plan? The Apify free plan includes $5 of monthly platform credits. At $0.045 per tool call, that covers approximately 111 individual tool calls or 111 comprehensive pipeline threat reports per month on free credits alone, since all tools are priced equally.

Can I use this MCP in an automated workflow without a human reviewing each call? Yes. The HTTP endpoint accepts standard JSON-RPC 2.0 requests and returns structured JSON suitable for programmatic parsing. Set a spending limit in Apify Console to control costs in automated pipelines, and use the riskLevel field as a filter to trigger downstream actions only for HIGH or CRITICAL scores.

Help us improve

If you encounter issues, you can help us debug faster by enabling run sharing in your Apify account:

1. Go to Account Settings > Privacy
2. Enable Share runs with public Actor creators

This lets us see your run details when something goes wrong, so we can fix issues faster. Your data is only visible to the actor developer, not publicly.

Troubleshooting

Pipeline threat report returns mostly zeros across sub-models. This usually means the drug name query returned no results from one or more underlying sources. Try the active ingredient name (INN) instead of the brand name. Verify the drug is indexed in ClinicalTrials.gov and PubMed by searching both databases directly. If the drug is very new, it may not yet appear in all seven sources.

Adverse event divergence shows NORMAL but the drug is known to have safety issues. FAERS relies on voluntary adverse event reporting. Under-reporting is a well-documented limitation of the system. High-profile safety signals may be well-represented; post-marketing, long-term, or rare events may not be captured in the public FAERS snapshot.

Patent exclusivity years show 0 despite the drug being on patent. The patent search uses a text query and may not return the correct drug patents if the compound is indexed under a chemical name, SMILES string, or assignee variation. Try querying the assignee company name alongside the drug name, or the mechanism of action, in the track_patent_exclusivity tool.

Tool calls are slow or timing out. The comprehensive report tool runs 7 actors in parallel with a 120-second per-actor timeout. If the Apify platform is under load or an upstream government API is slow, individual actors may time out. The server uses Promise.allSettled, so partial results are still returned. For time-sensitive use cases, run individual tools rather than the comprehensive report.

Spending limit reached error after a few calls. Each tool call charges $0.045. If your Apify account has a low monthly or per-run spending limit set, it will be reached quickly during multi-tool AI research sessions. Increase the spending limit in Apify Console under the actor's run settings.

Responsible use

• This MCP queries publicly available government databases: FDA, EMA, ClinicalTrials.gov, USPTO, and NIH PubMed.
• Adverse event data from FAERS represents voluntary reports and should not be used as the sole basis for clinical or regulatory decision-making.
• Patent analysis output is for competitive intelligence purposes only and does not constitute legal advice or a freedom-to-operate opinion.
• Do not use pipeline threat scores as investment advice without corroborating with primary sources, financial analysis, and professional judgment.
• For guidance on web scraping and public data usage legality, see Apify's guide.

Support

Found a bug or have a feature request? Open an issue in the Issues tab on this actor's page. For custom integrations, enterprise pharmacovigilance workflows, or additional scoring model requirements, reach out through the Apify platform.